Infection Risk and Safety of Corticosteroid Use

被引:322
作者
Youssef, Jameel [1 ]
Novosad, Shannon A. [1 ]
Winthrop, Kevin L. [1 ]
机构
[1] Oregon Hlth & Sci Univ, Portland, OR 97239 USA
基金
美国国家卫生研究院;
关键词
Corticosteroids; Bacterial infections; Rheumatic diseases; Opportunistic infections; ANTITUMOR NECROSIS FACTOR; PNEUMOCYSTIS-CARINII-PNEUMONIA; SYSTEMIC-LUPUS-ERYTHEMATOSUS; LOW-DOSE PREDNISOLONE; MODIFYING ANTIRHEUMATIC DRUGS; SERIOUS BACTERIAL-INFECTIONS; ACTIVE RHEUMATOID-ARTHRITIS; IMMUNE-MEDIATED DISEASES; QUANTIFERON-TB GOLD; HERPES-ZOSTER;
D O I
10.1016/j.rdc.2015.08.004
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Corticosteroids are frequently used to treat rheumatic diseases. Their use comes with several well-established risks, including osteoporosis, avascular necrosis, glaucoma, and diabetes. The risk of infection is of utmost concern and is well documented, although randomized controlled trials of short-term and lower-dose steroids have generally shown little or no increased risk. Observational studies from the real world, however, have consistently shown dose-dependent increases in risk for serious infections as well as certain opportunistic infections. In patients who begin chronic steroid therapy, vaccination and screening strategies should be used in an attempt to mitigate this risk.
引用
收藏
页码:157 / +
页数:22
相关论文
共 87 条
  • [1] [Anonymous], 2000, MMWR Recomm Rep, V49, P1
  • [2] [Anonymous], REC AD IMM SCHED US
  • [3] [Anonymous], 2015, CONTR PREC COMM US V
  • [4] Arenas Miras Mdel M, 2014, BIOMED RES INT, V2014
  • [5] Low-Dose Prednisone Inclusion in a Methotrexate-Based, Tight Control Strategy for Early Rheumatoid Arthritis A Randomized Trial
    Bakker, Marije F.
    Jacobs, Johannes W. G.
    Welsing, Paco M. J.
    Verstappen, Suzanne M. M.
    Tekstra, Janneke
    Ton, Evelien
    Geurts, Monique A. W.
    van der Werf, Jacobine H.
    van Albada-Kuipers, Grietje A.
    Jahangier-de Veen, Zalima N.
    van der Veen, Maaike J.
    Verhoef, Catharina M.
    Lafeber, Floris P. J. G.
    Bijlsma, Johannes W. J.
    [J]. ANNALS OF INTERNAL MEDICINE, 2012, 156 (05) : 329 - U138
  • [6] QuantiFERON-TB Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases
    Bartalesi, F.
    Vicidomini, S.
    Goletti, D.
    Fiorelli, C.
    Fiori, G.
    Melchiorre, D.
    Tortoli, E.
    Mantella, A.
    Benucci, M.
    Girardi, E.
    Cerinic, M. M.
    Bartoloni, A.
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2009, 33 (03) : 586 - 593
  • [7] T-HELPER CELL DYSFUNCTION IN SYSTEMIC LUPUS-ERYTHEMATOSUS (SLE) - RELATION TO DISEASE-ACTIVITY
    BERMAS, BL
    PETRI, M
    GOLDMAN, D
    MITTLEMAN, B
    MILLER, MW
    STOCKS, NI
    VIA, CS
    SHEARER, GM
    [J]. JOURNAL OF CLINICAL IMMUNOLOGY, 1994, 14 (03) : 169 - 177
  • [8] Should Pneumocystis jiroveci prophylaxis be recommended with Rituximab treatment in ANCA-associated vasculitis?
    Besada, Emilio
    Nossent, Johannes C.
    [J]. CLINICAL RHEUMATOLOGY, 2013, 32 (11) : 1677 - 1681
  • [9] GLUCOCORTICOID THERAPY FOR IMMUNE-MEDIATED DISEASES - BASIC AND CLINICAL CORRELATES
    BOUMPAS, DT
    CHROUSOS, GP
    WILDER, RL
    CUPPS, TR
    BALOW, JE
    [J]. ANNALS OF INTERNAL MEDICINE, 1993, 119 (12) : 1198 - 1208
  • [10] Antirheumatic drugs and the risk of tuberculosis
    Brassard, Paul
    Kezouh, Abbas
    Suissa, Samy
    [J]. CLINICAL INFECTIOUS DISEASES, 2006, 43 (06) : 717 - 722